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ABSTRACT
Objectives: This study aimed to investigate and compare the pregnancy and live birth rates in IVF cycles of frozen-thawed 
embryo transfers and fresh embryo transfers in a group of women with a high risk of Ovarian hyperstimulation syndrome 
(OHSS). 
Material and methods: The study group consisted of 254 women with a high level of response to controlled ovarian hy-
perstimulation. The patients who received fresh cycle embryo transfers with calcium infusions are referred to as the Fresh 
Ca+ group, and those without the calcium therapy are called the Fresh Ca- group; and we used correspondingly similar 
terminology for the Frozen group. 
Results: We observed no statistically significant differences between the cycles of fresh and frozen-thawed embryo transfers 
in patients with a high risk of OHSS in terms of implantation, clinical pregnancy, and live birth rates. Furthermore, these 
implantation, clinical pregnancy and live birth rates were not different in the cycles with or without calcium treatment. 
There was no statistical difference in the OHSS rates between the fresh and frozen-thawed cycles; although, the OHSS rates 
were less in the two calcium infusion groups (Fresh Ca+ and Frozen-thawed Ca+) than in the without-calcium group. There 
was no OHSS development in the subjects of the Frozen-thawed Ca+ group. 
Conclusions: Our study results suggest that fresh and frozen-thawed embryo transfers have similar IVF results in patients 
with a high risk of OHSS. Calcium infusion is beneficial in preventing OHSS without altering pregnancy rates. Both IVF 
protocols with calcium infusion can safely be applied in high-responder patients without lowering success rates.
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INTRODUCTION
The quality of the embryo, and of endometrial recepti-
vity, and a well-balanced embryo-endometrium interaction 
are the most important determinants of success in Assisted 
Reproduction Techniques (ART) [1]. There is evidence that 
exposure to high levels of estrogen (E2) and progesterone 
(P) during controlled ovarian stimulation (COS) leads to bio-
chemical and morphological modifications and can impair 
endometrial receptivity [2–4]. Such changes in turn lead to 
an asynchrony between the embryo and the endometrium, 
which can cause the impairment of the embryo implantation 
[5]. However, to date, there is no consensus about the thre-
shold at which a cycle becomes supraphysiological leading 
to changes in endometrial receptivity [6].
Frozen embryo transfer (FET) pregnancy rates were 
higher in studies comparing IVF cycles of both fresh and 
frozen embryo transfers [5, 7, 8]. These studies show that 
in transfers of fresh embryos, the endometrial receptivity 
is impaired because of the high levels of estrogen during 
controlled ovarian hyperstimulation; and for that reason, 
fresh embryo transfers may have lower implantation 
chances with resulting lower pregnancy rates. Comparing 
the group where the best embryo was obtained for fresh 
transfer (and the remaining embryos were frozen for a later 
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frozen-thawed cycle) with the group of women whose em-
bryos were all frozen before any transfer, the latter group 
showed better results than the subsequent frozen-thawed 
cycles for the former group where the best embryo available 
was only the “second best” [9].
A freeze-all method is also one of the effective ways to 
eliminate the risk of ovarian hyperstimulation syndrome 
(OHSS) during the ART cycle [10]. OHSS is one of the major 
complications of COS; and it is iatrogenic and potentially 
lethal at present [11].
Objectives
In this study, we aimed to investigate and compare the 
pregnancy and live birth rates of two groups of women with 
a high risk of Ovarian hyperstimulation syndrome (OHSS) who 
underwent IVF cycles of frozen-thawed embryo transfers and 
fresh embryo transfers (wherein all the embryos obtained 
from the fresh cycle were frozen and the embryos were only 
transferred after thawing, at a later stage, in a subsequent cyc-
le, during which the endometrium was artificially prepared. 
MATERIAL AND METHODS
This is a retrospective study of a total of 254 patients who 
underwent ICSI in a private IVF center between 2013 and 
2016. The study group consisted of women with a high 
response to controlled ovarian hyperstimulation (high re-
sponder). Patients with a total follicle count of 15 or more 
and/or an estradiol (E2) value of over 3000 pg/mL on the day 
of ovulation induction were considered as high responders 
and with a high risk of OHSS. Exclusions from our study: 
patients over 40 years old, male factor, recurrent pregnancy 
loss stories, uterine pathologies, chronic systemic medical 
problems, systemic drug use, and agonist-induced.
The patients in our study were divided into four groups: 
those who received IVF cycles of fresh embryo transfer with 
calcium infusion (Fresh Ca+ group), those with fresh embryo 
transfers without calcium therapy (Fresh Ca- group), those 
who received IVF cycles of frozen-thawed embryo transfers 
with calcium infusions (Frozen Ca+ group), and those with 
frozen-thawed embryo transfers without calcium treatment 
(Frozen Ca- group).
In our study, gonadotropin-releasing hormone (GnRH) 
agonist and GnRH antagonist protocols were administered 
in patients during COS. 
During the agonist protocol, GnRH agonist 0.5 mg/day 
leuprolide acetate (Lucrin Daily; Abbott, Istanbul, Turkey) 
was started in the luteal phase of the previous cycle and 
recLH treatments were added in addition to recFSH, HMG or 
recFSH on the second and third days of the cycle. Drugs used 
in these treatments included recombinant human follicle sti-
mulated hormone (Rec-hFSH); either follitropin-α (Gonal-F®; 
Ares Serono, Geneva, Switzerland) or follitropin-β (Puregon®; 
Organon, Oss, the Netherlands); either human menopausal 
gonadotropin (HMG) (Menogon®; Ferring, Istanbul, Turkey) 
or highly purified human menopausal gonadotropin (HP-
-HMG) (Menopur®; Ferring, Istanbul, Turkey); and recLH (Lu-
veris; Merck Serono, Istanbul, Turkey).
In the antagonist protocol, we commenced the gona-
dotrophins on the second or third day of the cycle, and 
cetrorelix (Cetrotide®; Merck Serono, Turkey) was added to 
the treatment as a GnRH antagonist, when the dominant 
follicle was 14 mm. 
In both protocols, the development of the follicles was 
followed by transvaginal USG and E2. When the dominant 
follicle measurement was 19 mm or more, or at least three 
follicles were 17 mm or more, gonadotropin administration 
was terminated, and ovulation was induced. Ovulation was 
induced with 250 µg of human recombinant hCG (Ovitrelle®, 
Merck Serono, Turkey). Oocyte retrieval was performed du-
ring the transvaginal USG process between the 36th and 40th 
hour after ovulation was induced, and this was followed by 
intracytoplasmic sperm injection (ICSI) with mature oocytes 
and fresh sperm. 
Our study involved embryo transfers at the fresh cycle 
for 181 patients; and 73 patients in the frozen-thawed group 
whose embryos were frozen in total at the ovarian stimula-
tion cycle and then transferred at a later stage. Vitrification 
was employed to freeze the embryos. 
Calcium infusion was performed in 72 patients of the 
total group and in 28 patients of the total frozen group. 
Calcium infusion was administered intravenously by adding 
10% calcium gluconate (one gr/10 mL) in ampules into the 
physiologic saline. In addition, calcium infusion was admi-
nistered as one gram on the day of the hCG induction and 
as two grams on the oocyte retrieval day. The standard pro-
tocol of our clinic is for all patients with a high risk of OHSS, 
including all the patients in our study to receive 0.5 mg/day 
cabergoline tablets (Dostinex®, Pharmacia, Berlin, Germany) 
until the day of their embryo transfer when more than 12 fol-
licles are observed to be over 14 mm.
In both study groups (fresh and frozen-thawed cycles), 
we only selected those patients who underwent blastocyst 
transfer. The preparation of endometrium in all the thaw cyc-
les was performed using transdermal estrogen (Estraderm 
TTS; Novartis, Istanbul, Turkey). The luteal phase support 
started on the day of oocyte retrieval. All patients received 
vaginal micronized progesterone in gel form (Crinone 8%; 
Merck Serono, Istanbul, Turkey) in a single daily administra-
tion. Progesterone was used until nine weeks, if pregnancy 
was confirmed.
RESULTS
A total of 254 high-responder patients were included 
in our study. Fresh embryo transfers were performed on 
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181 patients (71.2%), while frozen-thawed embryo transfers 
were performed on 73 patients (28.7%). Calcium treatment 
was administered to 109 patients (60%) in the fresh groups; 
and 45 (61.6%) of these patients received the calcium treat-
ment as part of their frozen-thawed transfer. Table 1 shows 
the patients’ ages, body mass index (BMI), hormonal values 
at the beginning of the IVF cycle, infertility duration and 
which IVF cycle.
The results of our transvaginal USG and ovarian evalu-
ation of the study patients show that 149 (58%) of them had 
a normofollicular appearance, and 105 (41.3%) of them had 
a polycystic ovary (PCO) appearance. Among the patients 
who appeared to have PCO, 84 (80%) were diagnosed with 
polycystic ovary syndrome (PCOS) and 21 (20%) were dia-
gnosed with PCO. The menstruation cycles were regular in 
172 (67.7%) of our patients, whereas they were irregular 
in 82 (32.2%) of the patients. 221 patients (87%) were dia-
gnosed with primary infertility, whereas 33 (12.9%) were 
diagnosed with secondary infertility. 15 (5.9%) patients had 
a previous OHSS history. In addition, one had had OHSS 
twice and another patient had had OHSS three times.
Considering the COS protocols used in the study: in the 
fresh cycles, we used the antagonist protocol with 121 pa-
tients (66.8%) and the long-agonist protocol with 60 (33.1%); 
and in the frozen cycles we used the antagonist protocol 
with 60 (82.1%) of the patients and the long-agonist pro-
tocol with 13 patients (17.8%). 
In the study’s administration of drugs, 142 patients 
(79.0%) received FSH, 16 patients (8.8%) received HMG, 
12 patients (6.6%) received FSH+HMG, and 10 patients 
(5.5%) received FSH+LH. Of the patients in the frozen groups, 
58 (79.4%) received FSH, 11 (15%) received HMG, one (1.3%) 
received FSH+HMG, and three (4.1%) received FSH+LH.
In the ovulation induction process, of the fresh gro-
ups, 138 patients (76.2%) received rec-hCG and 43 patients 
(23.7%) received urinary hCG. Of the patients in the frozen 
groups, 46 (63.0%) received rec-hCG and 27 (36.9%) rece-
ived u-hCG. 
Table 2 shows the comparative characteristics of the 
cycle for the four study groups. Table 3 shows the compa-
rative results of the cycle for the four groups. There were 
no statistically significant differences between the groups 
for implantation rates, clinical pregnancy rates, and live 
birth rates.
The study showed the OHSS development rates across 
the groups as follows: 2 individuals (1.8%) in the Fresh Ca+ 
group, 6 (8.3%) in the Fresh Ca- group, none (0%) in the 
Frozen Ca+ group, and 1 (3.6%) in the Frozen Ca- group. 
There was no statistically significant correlation between 
the groups’ rates of OHSS development (p = 0.065). When 
the OHSS development rates of the 2 frozen groups were 
compared with those of the two fresh groups, development 
occurred in 8 patients (4.4%) of the combined frozen groups, 
and in 1 (1.4%) of the combined fresh groups. There was no 
statistically significant correlation between the results for 
the fresh and frozen groups’ rates of OHSS development 
(p = 0.453). When the OHSS development rates of those 
patients who received calcium was compared with those 
who did not receive calcium, OHSS developed in 2 (1.3%) of 
the former, and in 7 (7.0%) of the latter group that did not 
receive calcium treatment. There was a statistically signifi-
cant difference between the OHSS development results for 
these two with- and without-calcium (p = 0.031).
In the Fresh Ca+ group, early OHSS developed in 
1 (50.0%) patient, and late OHSS developed in 1 (50.0%) 
other. In the Fresh Ca- group, 2 (33.3%) of the 6 patients 
were early OHSS, whereas 4 (66.7%) of the 6 patients were 
late OHSS. In the Frozen Ca- group, early OHSS developed 
in one (100.0%) patient.
Comparing the patients who developed OHSS, 4 (44.4%) 
had mild OHSS, 4 (44.4%) had moderate OHSS, and 1 (11.2%) 
had severe OHSS. Distribution of these individuals across the 
study groups was as follows: one patient with mild OHSS 
and one with moderate OHSS in the Fresh Ca+ group; three 
patients with mild OHSS, two with moderate OHSS, and one 
with severe OHSS in the Fresh Ca- group; and one patient 
with moderate OHSS in the Frozen Ca-.
Three (33.3%) of the nine patients developing OHSS 
required hospitalization. Two (66.7%) of those patients were 
in the Fresh Ca- group, while 1 (33.3%) was in the Frozen 
Ca- group.
Two (22.2%) patients with OHSS had abdominal asci-
tes. One (50.0%) of these patients was in the Fresh Ca- group, 
and the other 1 (50.0%) was in the Frozen Ca- group.
DISCUSSION
Our study showed no statistically significant differences 
in the rates of implantation, clinical pregnancies, and live 
births between the fresh and frozen-thawed cycles in pa-
tients with a high risk of OHSS. Furthermore, these rates of 
implantation, clinical pregnancies, and live births were not 
differentiated when comparing the cycles with or without 
calcium treatment. The OHSS development rates were not 
statistically different when comparing the fresh and thawed 
cycles; however, when comparing the Ca+ and Ca- groups, 
the rate of OHSS development was significantly less in the 
former. OHSS did not develop in the members of the total 
freeze group with Ca infusion.
Previous studies have found that supraphysiological es-
trogen levels had detrimental effects on oogenesis, embryo 
development, endometrial receptivity and implantation 
rates in patients with an over-response to COS [12–14]. In the 
literature, the frozen-thawed embryo transfer was presented 
as a good option to protect embryos from endometrium 
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Table 3. Comparison of pregnancy results for the fresh and frozen-thawed embryo transfer groups, with and without calcium treatment
Variables
Group
p value
Fresh Ca+ Fresh Ca– Frozen Ca+ Frozen Ca–
Implantation rate per cycle, n (%) 49 (45.0) 31 (43.1) 21 (46.7) 13 (46.4) 0.980
Implantation rate per ET, n (%) 49 (31.0) 31 (29.2) 21 (30.0) 13 (34.2) 0.951
Clinical pregnancy rate per cycle, n (%) 46 (42.2) 28 (38.9) 18 (40.0) 11 (39.2) 0.973
Clinical pregnancy rate per ET, n (%) 46 (29.1) 28 (26.4) 18 (25.7) 11 (28.9) 0.938
Live birth rate per cycle, n (%) 46 (42.2) 26 (36.1) 16 (35.6) 9 (32.1) 0.696
Live birth rate per ET, n (%) 46 (29.1) 26 (24.5) 16 (22.9) 9 (23.7) 0.711
exposed to high estrogen [9, 15]. At the same time, a freeze-
-all strategy has become an extremely popular method of 
protecting against OHSS [16]. 
Comparisons of fresh and frozen-thawed cycles display-
ed different results. The methodologies, and therefore the 
data, of four large randomized controlled studies we revie-
wed and discuss in this paragraph were quite different from 
each other. Chen et al. [17] reported higher live birth rates 
following frozen embryo transfers in PCOS patients than in 
patients from the fresh group. Shapiro et al. [7] reported 
that implantation rates in normoresponder frozen thawed 
cycles were higher than both the clinical and ongoing pre-
gnancy rates from fresh cycles, and they attributed these 
results to the impaired endometrial receptivity of the fresh 
cycles. Shapiro et al. [18] found no difference between cli-
nical and ongoing pregnancy rates in high responder pa-
tients. Ferraretti et al. [19] examined the difference between 
fresh and frozen-thawed transfers in patients with a risk of 
OHSS and did not find any differences between the resulting 
pregnancies and live birth rates for either group. 
Our study was conducted with only high responder 
subjects with a high risk of OHSS who underwent cycles of 
blastocyst transfer with fresh and frozen-thawed embry-
os, and there was no statistically significant difference in 
pregnancy rates between those fresh and frozen-thawed 
groups. The reason why only included patients who had 
undergone blastocyst transfers in our study was to homo-
genize the study group. Discussions in the literature on the 
relative effects of blastocyst versus cleavage-stage embryo 
transfers on the maternal and neonatal outcomes are ongo-
ing, as are discussions on the effects on implantation and 
pregnancy rates [20–23]. 
Gurgan et al. [24] published a study in 2011 demonstra-
ting that calcium infusion reduced the risk of developing 
OHSS. In the following years, more studies supporting this 
finding were published [25, 26]. Calcium infusion is used for 
OHSS prevention in the group with high OHSS risk in our 
clinic. In our study, along with comparing fresh and frozen-
-thawed cycles, we compared the pregnancy rates of the 
groups with and without calcium and it was found that there 
was no significant difference in the pregnancy rates. Though 
the risk of OHSS development was significantly reduced 
in the group receiving calcium treatment, we did observe 
early and moderate OHSS in this group, along with the need 
for hospitalization, and abdominal ascites; however, severe 
OHSS did not develop. Khayat et al. [25] found no difference 
in implantation and pregnancy rates between groups using 
and not using calcium, whereas Gurgan et al. [24] reported 
that pregnancy rates were higher in the calcium-treated 
group than in the group not receiving calcium.
One of the most successful methods of protecting against 
OHSS is the use of agonist induction [27]. There are contra-
sting conclusions in the literature on the topic of the effects of 
agonist induction versus hCG induction on implantation and 
pregnancy rates [28, 29]. Our study did not include an agonist 
induction group. Since the primary outcome of our study was 
to compare pregnancy rates resulting from groups of fresh 
and frozen-thawed cycles, instead of OHSS development 
rates, only hCG induction cycles were included in the study. 
In this way the effects of agonist induction on the pregnancy 
rates of our subjects were eliminated. By the same logic, our 
study did not include cleavage-stage embryo transfers; the-
refore, any difference in pregnancy rates between cleavage-
-stage and blastocyst was also excluded. 
Our study is the first involving subjects with a high risk 
of OHSS who underwent cycles of blastocyst transfer to 
compare the results of fresh and frozen-thawed embryo 
transfers. In this respect, we believe that our study will con-
tribute to the literature. The main limitation of our study is 
its retrospective nature. 
In conclusion, our study results suggest that fresh and 
frozen-thawed embryo transfers have similar IVF results 
among patients with a high risk of OHSS. Calcium infusion 
is beneficial in preventing OHSS without altering pregnancy 
rates. Both calcium infusion protocols can be safely applied 
in high-responder patients without lowering success rates.
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